Diagnosis and management of iron deficiency in chronic dialysis patients

被引:4
作者
van Zyl-Smit, R [1 ]
机构
[1] Univ Cape Town, Groote Schuur Hosp, Dept Med, Renal Unit E13,Observ 7935, ZA-7925 Cape Town, South Africa
关键词
D O I
10.1097/00041552-200011000-00013
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Tests have become available that not only give an index of iron stores and availability but also provide an integrated assessment of the efficacy of its utilization. This has allowed the revision of previously accepted criteria of iron deficiency as well as the most appropriate strategies for iron administration. By optimizing the response to erythropoietin, target haemoglobin levels may be reached with smaller doses, resulting in substantial savings. Curr Opin Nephrol Hypertens 9:669-674. (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:669 / 674
页数:6
相关论文
共 39 条
[1]   A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients [J].
Auerbach, M ;
Winchester, J ;
Wahab, A ;
Richards, K ;
McGinley, M ;
Hall, F ;
Anderson, J ;
Briefel, G .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (01) :81-86
[2]   Parenteral iron use in the management of anemia in end-stage renal disease patients [J].
Bailie, GR ;
Johnson, CA ;
Mason, NA .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (01) :1-12
[3]   A study of parenteral iron regimens in hemodialysis patients [J].
Besarab, A ;
Kaiser, JW ;
Frinak, S .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (01) :21-28
[4]  
Besarab A, 1999, J AM SOC NEPHROL, V10, P2029
[5]  
Besarab A, 2000, J AM SOC NEPHROL, V11, P530, DOI 10.1681/ASN.V113530
[6]   Iron and cardiac disease in the end-stage renal disease setting [J].
Besarab, A .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (04) :S18-S24
[7]   Factors determining the percentage of hypochromic red blood cells in hemodialysis patients [J].
Bovy, C ;
Tsobo, C ;
Crapanzano, L ;
Rorive, G ;
Beguin, Y ;
Albert, A ;
Paulus, JM .
KIDNEY INTERNATIONAL, 1999, 56 (03) :1113-1119
[8]   Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients [J].
Braun, J ;
Lindner, K ;
Schreiber, M ;
Heidler, RA ;
Horl, WH .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (06) :1173-1181
[9]   Toxicity of parenteral iron dextran therapy [J].
Burns, DL ;
Pomposelli, JJ .
KIDNEY INTERNATIONAL, 1999, 55 :S119-S124
[10]  
Canavese C, 2000, CLIN NEPHROL, V53, P42